Nifty
Sensex
:
:
10087.45
32585.46
66.80 (0.67%)
203.00 (0.63%)

Chemicals

Rating :
72/99   (View)

BSE: 530019 | NSE: JUBILANT

743.55
3.65 (0.49%)
27-Jul-2017 | 10:14AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 742.65
  • 749.20
  • 740.05
  • 739.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 44395
  • 330.10
  • 878.00
  • 315.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,771.67
  • 20.98
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,151.77
  • 0.40%
  • 3.29

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.02%
  • 3.54%
  • 13.98%
  • FII
  • DII
  • Others
  • 0.89%
  • 4.02%
  • 23.55%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 17
Jun 16
Var%
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Net Sales
1,596.05
1,419.53
12.44%
1,641.42
1,501.27
9.34%
1,458.22
1,379.45
5.71%
1,385.50
1,463.05
-5.30%
Expenses
1,258.44
1,051.37
19.70%
1,336.44
1,183.31
12.94%
1,126.40
1,074.44
4.84%
1,045.17
1,142.47
-8.52%
EBITDA
337.61
368.16
-8.30%
304.98
317.96
-4.08%
331.82
305.01
8.79%
340.33
320.58
6.16%
EBIDTM
21.15%
25.94%
18.58%
21.18%
22.25%
22.11%
23.98%
21.91%
Other Income
6.81
4.29
58.74%
10.53
2.52
317.86%
5.12
2.85
79.65%
4.92
4.47
10.07%
Interest
68.73
82.77
-16.96%
80.19
89.93
-10.83%
98.19
90.01
9.09%
79.96
97.42
-17.92%
Depreciation
72.48
71.52
1.34%
75.22
126.02
-40.31%
72.65
74.65
-2.68%
72.01
75.10
-4.11%
PBT
203.21
218.26
-6.90%
160.10
120.99
32.32%
166.48
139.96
18.95%
193.43
154.84
24.92%
Tax
59.50
54.24
9.70%
11.07
50.31
-78.00%
47.99
23.03
108.38%
49.72
39.02
27.42%
PAT
143.71
164.02
-12.38%
149.03
70.68
110.85%
118.49
116.93
1.33%
143.71
115.82
24.08%
PATM
9.00%
11.55%
9.08%
4.71%
7.94%
8.48%
10.13%
7.92%
EPS
9.45
10.14
-6.80%
9.64
4.44
117.12%
7.69
7.34
4.77%
9.31
7.27
28.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Net Sales
5,802.32
5,826.25
5,803.36
5,165.95
4,303.13
3,445.62
3,791.13
3,517.98
2,488.34
1,808.87
Net Sales Growth
-0.41%
0.39%
12.34%
20.05%
24.89%
-9.11%
7.76%
41.38%
37.56%
 
Cost Of Goods Sold
2,116.20
2,663.02
2,438.46
2,062.85
1,618.87
1,339.68
1,471.11
1,352.42
986.26
830.33
Gross Profit
3,686.13
3,163.23
3,364.90
3,103.10
2,684.26
2,105.95
2,320.02
2,165.57
1,502.08
978.54
GP Margin
63.53%
54.29%
57.98%
60.07%
62.38%
61.12%
61.20%
61.56%
60.36%
54.10%
Total Expenditure
4,513.72
5,124.71
4,782.37
4,097.81
3,412.94
2,880.76
3,111.07
2,834.73
2,034.35
1,546.77
Power & Fuel Cost
366.71
393.04
389.74
356.73
286.89
224.04
220.03
197.91
170.43
130.48
% Of Sales
6.32%
6.75%
6.72%
6.91%
6.67%
6.50%
5.80%
5.63%
6.85%
7.21%
Employee Cost
1,126.73
1,090.28
1,105.17
962.58
836.36
718.54
735.21
648.49
375.71
211.26
% Of Sales
19.42%
18.71%
19.04%
18.63%
19.44%
20.85%
19.39%
18.43%
15.10%
11.68%
Manufacturing Exp.
436.46
432.40
405.14
360.48
329.75
284.66
315.90
293.91
230.80
169.05
% Of Sales
7.52%
7.42%
6.98%
6.98%
7.66%
8.26%
8.33%
8.35%
9.28%
9.35%
General & Admin Exp.
256.56
302.28
264.23
208.35
200.72
195.72
196.68
191.38
137.43
102.35
% Of Sales
4.42%
5.19%
4.55%
4.03%
4.66%
5.68%
5.19%
5.44%
5.52%
5.66%
Selling & Distn. Exp.
189.08
203.98
160.04
123.28
111.85
90.92
125.97
124.22
107.56
91.16
% Of Sales
3.26%
3.50%
2.76%
2.39%
2.60%
2.64%
3.32%
3.53%
4.32%
5.04%
Miscellaneous Exp.
21.98
39.72
19.59
23.53
28.50
27.21
46.18
26.41
26.15
91.16
% Of Sales
0.38%
0.68%
0.34%
0.46%
0.66%
0.79%
1.22%
0.75%
1.05%
0.67%
EBITDA
1,288.60
701.54
1,020.99
1,068.14
890.19
564.86
680.06
683.25
453.99
262.10
EBITDA Margin
22.21%
12.04%
17.59%
20.68%
20.69%
16.39%
17.94%
19.42%
18.24%
14.49%
Other Income
13.64
42.45
19.06
29.87
31.48
17.24
118.09
106.66
144.41
125.95
Interest
389.40
367.61
337.11
310.93
238.23
119.99
155.57
330.09
38.36
30.46
Depreciation
345.98
287.95
281.17
253.79
220.65
180.10
124.68
163.24
103.91
62.29
PBT
566.87
88.43
421.78
533.29
462.79
282.02
517.90
296.58
456.13
295.30
Tax
152.85
80.48
69.64
152.36
68.41
13.37
95.94
26.72
57.28
71.25
Tax Rate
26.16%
199.55%
33.60%
44.66%
59.95%
5.56%
18.52%
9.01%
12.56%
24.13%
PAT
431.49
-57.76
109.04
152.73
14.56
229.72
421.46
283.18
400.50
228.00
PAT before Minority Interest
431.49
-40.16
137.64
188.78
45.69
227.23
421.95
269.86
398.85
224.06
Minority Interest
0.00
-17.60
-28.60
-36.05
-31.13
2.49
-0.49
13.32
1.65
3.94
PAT Margin
7.44%
-0.99%
1.88%
2.96%
0.34%
6.67%
11.12%
8.05%
16.10%
12.60%
PAT Growth
847.04%
-152.97%
-28.61%
948.97%
-93.66%
-45.49%
48.83%
-29.29%
75.66%
 
Unadjusted EPS
27.09
-3.63
6.85
9.59
0.91
14.42
28.56
19.22
27.28
15.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Shareholder's Funds
2,909.57
2,453.52
2,626.51
2,476.12
2,257.03
2,172.27
2,201.34
1,542.64
1,256.20
906.13
Share Capital
15.93
15.93
15.45
15.93
15.93
15.93
15.88
14.76
14.62
14.35
Total Reserves
2,893.64
2,437.59
2,611.07
2,460.19
2,241.10
2,156.34
2,185.46
1,527.89
1,241.50
891.76
Non-Current Liabilities
3,522.97
4,036.15
2,184.95
3,004.85
3,224.12
3,048.25
3,365.15
4,056.86
2,238.68
1,788.63
Secured Loans
2,646.48
3,316.29
1,716.67
1,708.74
2,839.47
2,435.91
2,160.79
2,966.30
1,058.59
417.17
Unsecured Loans
397.50
375.00
0.22
760.06
0.45
400.61
1,011.94
975.49
1,049.87
1,235.44
Long Term Provisions
70.46
67.04
219.53
237.96
169.70
39.87
0.00
0.00
0.00
0.00
Current Liabilities
2,514.48
2,129.16
3,894.41
2,778.35
2,212.79
2,269.67
1,220.11
1,130.63
667.91
524.81
Trade Payables
599.64
721.19
718.14
647.13
836.98
517.43
688.83
584.06
306.65
254.59
Other Current Liabilities
977.21
793.31
1,731.20
898.00
499.55
465.94
64.70
88.72
65.14
37.19
Short Term Borrowings
728.19
517.17
1,187.83
1,131.39
767.07
883.03
0.00
0.00
0.00
0.00
Short Term Provisions
209.44
97.49
257.25
101.84
109.18
403.28
466.59
457.85
296.13
233.03
Total Liabilities
8,947.02
8,618.83
8,863.81
8,370.86
7,762.89
7,532.00
6,824.52
6,762.08
4,184.18
3,236.98
Net Block
5,091.40
4,911.33
5,098.78
4,967.46
4,460.18
3,991.05
3,818.89
3,745.00
1,912.42
1,227.90
Gross Block
7,861.87
7,362.10
7,330.63
6,870.15
6,084.09
5,163.28
4,845.26
4,648.26
2,495.91
1,667.15
Accumulated Depreciation
2,770.47
2,450.76
2,231.85
1,902.69
1,623.92
1,172.22
1,026.38
903.26
583.49
439.25
Non Current Assets
6,045.70
5,904.29
5,935.78
5,809.80
5,465.57
4,940.25
4,357.21
4,281.34
2,402.01
1,464.45
Capital Work in Progress
593.56
596.60
472.39
436.89
685.55
666.71
505.63
503.12
484.69
235.69
Non Current Investment
36.11
39.50
33.99
25.61
19.20
32.75
32.70
33.22
4.90
0.87
Long Term Loans & Adv.
293.32
327.17
328.42
379.47
299.86
249.18
0.00
0.00
0.00
0.00
Other Non Current Assets
31.30
29.68
2.21
0.37
0.79
0.55
0.00
0.00
0.00
0.00
Current Assets
2,901.32
2,714.54
2,928.03
2,561.06
2,297.32
2,591.75
2,455.22
2,205.31
1,780.52
1,768.45
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
223.71
238.13
40.73
3.02
Inventories
1,216.06
1,235.33
1,341.42
1,116.18
1,020.22
691.28
690.95
595.61
434.97
353.24
Sundry Debtors
929.73
819.27
805.87
708.54
652.69
520.45
518.61
504.41
425.78
294.81
Cash & Bank
344.48
394.34
479.53
356.05
266.82
1,045.14
503.67
381.66
523.77
874.91
Other Current Assets
411.05
265.59
301.21
380.29
357.59
334.88
518.27
485.49
355.27
242.47
Short Term Loans & Adv.
246.93
144.56
136.04
182.01
256.70
217.50
498.14
444.09
323.54
228.91
Net Current Assets
386.84
585.38
-966.38
-217.29
84.53
322.08
1,235.11
1,074.69
1,112.61
1,243.64
Total Assets
8,947.02
8,618.83
8,863.81
8,370.86
7,762.89
7,532.00
6,824.51
6,762.08
4,184.18
3,236.98

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Cash From Operating Activity
1,092.30
783.26
772.27
969.90
707.17
389.75
709.61
558.06
257.47
190.64
PBT
584.34
40.32
207.28
341.14
114.11
240.59
517.90
296.58
456.13
295.30
Adjustment
702.67
725.84
756.60
752.36
795.44
318.42
189.22
352.94
34.70
7.55
Changes in Working Capital
-146.64
96.40
-110.70
-4.04
-136.91
-84.14
62.58
-55.56
-185.10
-88.62
Cash after chg. in Working capital
1,140.37
862.57
853.18
1,089.46
772.64
474.88
769.70
593.96
305.73
214.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-48.07
-79.31
-80.91
-119.56
-65.47
-85.14
-60.57
-41.99
-45.42
-35.57
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-326.45
-343.33
-174.42
-499.72
-594.31
-352.15
-279.75
-2,030.73
-1,139.35
-367.49
Net Fixed Assets
-59.56
1,162.43
-166.96
-286.05
-434.15
-275.33
-128.63
-492.68
-281.91
-251.03
Net Investments
59.43
239.81
-27.56
-18.79
-95.66
5.14
-159.67
-331.27
-102.45
-1,034.27
Others
-326.32
-1,745.57
20.10
-194.88
-64.50
-81.96
8.55
-1,206.78
-754.99
917.81
Cash from Financing Activity
-822.33
-502.69
-414.41
-449.76
-888.82
608.21
-298.02
1,150.66
592.81
962.95
Net Cash Inflow / Outflow
-56.48
-62.76
183.44
20.41
-775.95
645.81
131.84
-322.01
-289.08
786.10
Opening Cash & Equivalents
391.63
473.49
279.65
263.08
1,041.15
498.27
381.66
523.77
874.91
138.96
Closing Cash & Equivalent
339.17
391.63
473.49
279.65
263.08
1,041.15
505.34
375.89
523.82
874.93

Financial Ratios

Consolidated /

Standalone
Description
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Book Value (Rs.)
182.67
154.04
170.07
155.46
141.70
136.38
137.88
85.89
85.81
62.88
ROA
4.91%
-0.46%
1.60%
2.34%
0.60%
3.17%
6.21%
4.93%
10.75%
8.47%
ROE
16.09%
-1.58%
5.39%
7.98%
2.06%
10.42%
24.42%
21.40%
36.99%
25.98%
ROCE
13.27%
5.72%
7.92%
10.19%
5.79%
6.29%
12.74%
14.62%
16.71%
15.89%
Fixed Asset Turnover
0.78
0.81
0.84
0.82
0.78
0.70
0.82
1.02
1.26
1.27
Receivable days
53.68
49.56
46.53
47.00
48.71
53.83
48.18
46.63
50.03
50.97
Inventory Days
75.23
78.58
75.51
73.76
71.07
71.61
60.59
51.66
54.72
62.44
Payable days
52.31
52.17
51.42
45.33
38.70
50.95
58.42
49.77
49.78
50.27
Cash Conversion Cycle
76.60
75.98
70.61
75.42
81.08
74.50
50.34
48.52
54.97
63.14
Total Debt/Equity
1.55
1.95
1.67
1.71
1.69
1.81
1.45
3.11
1.68
1.83
Interest Cover
2.50
1.11
1.61
2.10
1.48
3.01
4.33
1.90
12.89
10.70

News Update


  • Rakesh Jhunjhunwala picks 1.26% stake in Jubilant Life Sciences
    21st Jul 2017, 09:36 AM

    The ace investor has purchased 20 lakh equity shares in the company during April-June quarter

    Read More
  • Jubilant receives ANDA approval for Bupropion Hydrochloride Tablets
    6th Jul 2017, 11:16 AM

    Bupropion Hydrochloride Tablets is the generic version of Wellbutrin XL of Valeant

    Read More
  • Jubilant Life Sciences resumes operations at Gajraula unit
    1st Jun 2017, 14:00 PM

    With this, manufacturing operations of all units at Gajraula have resumed

    Read More
  • Jubilant Life Sciences hikes price of Vitamin B3 up to 15%
    25th May 2017, 15:51 PM

    This is further to the price increase of up to 15% announced in December 2016

    Read More
  • Jubilant LifeScience - Quarterly Results
    23rd May 2017, 12:00 AM

    Read More
  • Jubilant’s arm gets ANDA approval for Amlodipine and Olmesartan Medoxomil Tablets
    17th May 2017, 12:27 PM

    This is the third approval that the company has received from the USFDA during the current financial year

    Read More
  • Jubilant Life Sciences resumes operations at Gajraula unit
    10th May 2017, 10:32 AM

    According to the company, the revenue impact of the distillery operations in FY- 2017 is not significant

    Read More
  • Jubilant Life Sciences’ arm to acquire radiopharmacy business of Triad Isotopes
    5th May 2017, 09:19 AM

    The acquisition will be funded through JPL’s internal accruals and is likely to be earnings accretive in the first full year of operations

    Read More
  • Jubilant Life Sciences receives credit rating of ‘A1+’ from CRISIL
    3rd May 2017, 10:46 AM

    The company has received credit rating for commercial paper programme of Rs 400 crore

    Read More
  • Jubilant Life Sciences issues commercial paper worth Rs 75 crore
    27th Apr 2017, 16:26 PM

    The aggregate amount of commercial papers outstanding as on date is Rs 175 crore

    Read More
  • Jubilant Life Sciences receives ANDA approval for Olmesartan Medoxomil Tablets
    25th Apr 2017, 10:40 AM

    As on December 31, 2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved

    Read More
  • Jubilant Life Sciences issues Commercial Paper worth Rs 100 crore
    18th Apr 2017, 14:25 PM

    The tenure of the instrument is 63 days and allotted on April 18, 2017

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.